Dr. Reddy’s Laboratories (RDY) to Release Earnings on Thursday

Dr. Reddy’s Laboratories (NYSE:RDY) will likely be issuing its Q3 25/26 results before the market opens on Thursday, January 22nd. Analysts expect the company to announce earnings of $0.16 per share and revenue of $963.8440 million for the quarter. Individuals may visit the the company’s upcoming Q3 25/26 earning results page for the latest details on the call scheduled for Wednesday, January 21, 2026 at 9:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Friday, October 24th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.18 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.14% and a return on equity of 17.13%. The company had revenue of $993.72 million for the quarter, compared to analyst estimates of $944.26 million. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Price Performance

Shares of Dr. Reddy’s Laboratories stock opened at $12.92 on Tuesday. The firm has a market cap of $10.79 billion, a PE ratio of 15.95, a P/E/G ratio of 6.11 and a beta of 0.37. Dr. Reddy’s Laboratories has a twelve month low of $12.26 and a twelve month high of $16.17. The company has a quick ratio of 1.35, a current ratio of 1.85 and a debt-to-equity ratio of 0.03. The business has a 50-day moving average price of $13.86 and a 200 day moving average price of $14.13.

Institutional Trading of Dr. Reddy’s Laboratories

Hedge funds have recently modified their holdings of the stock. Caisse de depot et placement du Quebec boosted its stake in shares of Dr. Reddy’s Laboratories by 167.8% in the 3rd quarter. Caisse de depot et placement du Quebec now owns 566,200 shares of the company’s stock valued at $7,915,000 after buying an additional 354,800 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of Dr. Reddy’s Laboratories during the 2nd quarter worth about $5,024,000. Creative Planning increased its holdings in shares of Dr. Reddy’s Laboratories by 15.3% in the 3rd quarter. Creative Planning now owns 1,262,891 shares of the company’s stock valued at $17,655,000 after acquiring an additional 167,959 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Dr. Reddy’s Laboratories by 92.6% during the second quarter. Quantinno Capital Management LP now owns 235,044 shares of the company’s stock worth $3,533,000 after purchasing an additional 112,988 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its holdings in Dr. Reddy’s Laboratories by 10.8% in the third quarter. Lazard Asset Management LLC now owns 770,025 shares of the company’s stock valued at $10,765,000 after purchasing an additional 75,177 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.90.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.